FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981204147> ?p ?o ?g. }

• W2981204147 abstract "Refractory anaphylaxis (unresponsive to treatment with at least two doses of minimum 300 μg adrenaline) is a rare and often fatal hypersensitivity reaction. Comprehensive data on its definition, prevalence, and risk factors are missing. Using the data from the European Anaphylaxis Registry (11,596 cases in total) we identified refractory anaphylaxis cases (n = 42) and analyzed these in comparison to a control group of severe anaphylaxis cases (n = 4,820). The data show that drugs more frequently elicited refractory anaphylaxis (50% of cases, p < 0.0001) compared to other severe anaphylaxis cases (19.7%). Cases elicited by insects (n = 8) were more often due to bees than wasps in refractory cases (62.5 vs. 19.4%, p = 0.009). The refractory cases occurred mostly in a perioperative setting (45.2 vs. 9.05, p < 0.0001). Intramuscular adrenaline (as a first line therapy) was administered in 16.7% of refractory cases, whereas in 83.3% of cases it was applied intravenously (significantly more often than in severe anaphylaxis cases: 12.3%, p < 0.0001). Second line treatment options (e.g., vasopression with dopamine, methylene blue, glucagon) were not used at all for the treatment of refractory cases. The mortality rate in refractory anaphylaxis was significantly higher (26.2%) than in severe cases (0.353%, p < 0.0001). Refractory anaphylaxis is associated with drug-induced anaphylaxis in particular if allergens are given intravenously. Although physicians frequently use adrenaline in cases of perioperative anaphylaxis, not all patients are responding to treatment. Whether a delay in recognition of anaphylaxis is responsible for the refractory case or whether these cases are due to an overflow with mast cell activating substances-requires further studies. Reasons for the low use of second-line medication (i.e., methylene blue or dopamine) in refractory cases are unknown, but their use might improve the outcome of severe refractory anaphylaxis cases." @default.
• W2981204147 created "2019-10-25" @default.
• W2981204147 creator A5013237778 @default.
• W2981204147 creator A5013757723 @default.
• W2981204147 creator A5026983374 @default.
• W2981204147 creator A5040724959 @default.
• W2981204147 creator A5048242371 @default.
• W2981204147 creator A5048797041 @default.
• W2981204147 creator A5051601997 @default.
• W2981204147 creator A5055384178 @default.
• W2981204147 creator A5078488796 @default.
• W2981204147 creator A5083184769 @default.
• W2981204147 date "2019-10-18" @default.
• W2981204147 modified "2023-10-11" @default.
• W2981204147 title "Refractory Anaphylaxis: Data From the European Anaphylaxis Registry" @default.
• W2981204147 cites W1466152204 @default.
• W2981204147 cites W1955400615 @default.
• W2981204147 cites W1963678166 @default.
• W2981204147 cites W1970532901 @default.
• W2981204147 cites W1976673929 @default.
• W2981204147 cites W1980259685 @default.
• W2981204147 cites W198309986 @default.
• W2981204147 cites W1984341466 @default.
• W2981204147 cites W1985227168 @default.
• W2981204147 cites W1998950078 @default.
• W2981204147 cites W2012913884 @default.
• W2981204147 cites W2018318330 @default.
• W2981204147 cites W2023665983 @default.
• W2981204147 cites W2028103113 @default.
• W2981204147 cites W2046181014 @default.
• W2981204147 cites W2048252063 @default.
• W2981204147 cites W2056811697 @default.
• W2981204147 cites W2064244980 @default.
• W2981204147 cites W2095238135 @default.
• W2981204147 cites W2100368015 @default.
• W2981204147 cites W2110553083 @default.
• W2981204147 cites W2117983722 @default.
• W2981204147 cites W2131560514 @default.
• W2981204147 cites W2132885099 @default.
• W2981204147 cites W2135015090 @default.
• W2981204147 cites W2137920458 @default.
• W2981204147 cites W2140341488 @default.
• W2981204147 cites W2160881996 @default.
• W2981204147 cites W2164623742 @default.
• W2981204147 cites W2257840317 @default.
• W2981204147 cites W2746951261 @default.
• W2981204147 cites W2782618799 @default.
• W2981204147 cites W2785480624 @default.
• W2981204147 cites W2790646319 @default.
• W2981204147 cites W2793226231 @default.
• W2981204147 cites W2795314623 @default.
• W2981204147 cites W2804053758 @default.
• W2981204147 cites W2805441868 @default.
• W2981204147 cites W2923114948 @default.
• W2981204147 cites W4252241851 @default.
• W2981204147 doi "https://doi.org/10.3389/fimmu.2019.02482" @default.
• W2981204147 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6842952" @default.
• W2981204147 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31749797" @default.
• W2981204147 hasPublicationYear "2019" @default.
• W2981204147 type Work @default.
• W2981204147 sameAs 2981204147 @default.
• W2981204147 citedByCount "36" @default.
• W2981204147 countsByYear W29812041472020 @default.
• W2981204147 countsByYear W29812041472021 @default.
• W2981204147 countsByYear W29812041472022 @default.
• W2981204147 countsByYear W29812041472023 @default.
• W2981204147 crossrefType "journal-article" @default.
• W2981204147 hasAuthorship W2981204147A5013237778 @default.
• W2981204147 hasAuthorship W2981204147A5013757723 @default.
• W2981204147 hasAuthorship W2981204147A5026983374 @default.
• W2981204147 hasAuthorship W2981204147A5040724959 @default.
• W2981204147 hasAuthorship W2981204147A5048242371 @default.
• W2981204147 hasAuthorship W2981204147A5048797041 @default.
• W2981204147 hasAuthorship W2981204147A5051601997 @default.
• W2981204147 hasAuthorship W2981204147A5055384178 @default.
• W2981204147 hasAuthorship W2981204147A5078488796 @default.
• W2981204147 hasAuthorship W2981204147A5083184769 @default.
• W2981204147 hasBestOaLocation W29812041471 @default.
• W2981204147 hasConcept C121332964 @default.
• W2981204147 hasConcept C126322002 @default.
• W2981204147 hasConcept C142424586 @default.
• W2981204147 hasConcept C203014093 @default.
• W2981204147 hasConcept C207480886 @default.
• W2981204147 hasConcept C2775859304 @default.
• W2981204147 hasConcept C2775933838 @default.
• W2981204147 hasConcept C42219234 @default.
• W2981204147 hasConcept C71924100 @default.
• W2981204147 hasConcept C87355193 @default.
• W2981204147 hasConceptScore W2981204147C121332964 @default.
• W2981204147 hasConceptScore W2981204147C126322002 @default.
• W2981204147 hasConceptScore W2981204147C142424586 @default.
• W2981204147 hasConceptScore W2981204147C203014093 @default.
• W2981204147 hasConceptScore W2981204147C207480886 @default.
• W2981204147 hasConceptScore W2981204147C2775859304 @default.
• W2981204147 hasConceptScore W2981204147C2775933838 @default.
• W2981204147 hasConceptScore W2981204147C42219234 @default.
• W2981204147 hasConceptScore W2981204147C71924100 @default.
• W2981204147 hasConceptScore W2981204147C87355193 @default.
• W2981204147 hasLocation W29812041471 @default.
• W2981204147 hasLocation W29812041472 @default.

• next